In silico prediction of drug safety: Despite progress there is abundant room for improvement

Drug Discovery Today: Technologies

Volumn 1, Issue 4, 2004, Pages 381-387

  Egan, William J ^a,b   Zlokarnik, Gregor ^a   Grootenhuis, Peter D J ^a  

^a VERTEX PHARMACEUTICALS   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYL 6 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; 4 IPOMEANOL; ANALGESIC AGENT; ANTIBIOTIC AGENT; ASTEMIZOLE; CISAPRIDE; CYTOCHROME P450; CYTOCHROME P450 3A4; DRUG; GREPAFLOXACIN; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM CHANNEL HERG; SERTINDOLE; SPIRONOLACTONE; TERFENADINE;

CARCINOGENICITY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; COMPUTER MODEL; COMPUTER PROGRAM; DOSE RESPONSE; DRUG CLEARANCE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; GENOTOXICITY; HEART ARRHYTHMIA; HUMAN; LIVER TOXICITY; MUTAGENICITY; NEPHROTOXICITY; NONHUMAN; PREDICTION; REVIEW;

EID: 13244277456     PISSN: 17406749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddtec.2004.11.002     Document Type: Review

References (25)

1. N. Greene Computer systems for the prediction of toxicity: An update Adv. Drug Deliv. Rev. 54 2002 417-431
2. R.D. Snyder et al. Assessment of the sensitivity of the computational programs DEREK, TOPKAT, and MCASE in the prediction of the genotoxicity of pharmaceutical molecules Environ. Mol. Mutagen. 43 2004 143-158
3. E.J. Matthews et al. Use of toxicological information in drug design J. Mol. Graphics Modell. 18 2000 605-615
4. J.F. Contrera et al. Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices Regul. Toxicol. Pharmacol. 38 2003 243-259
5. M. Fung et al. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets - 1960 to 1999 Drug Inf. J. 35 2001 293-317
6. D.E. Amacher Serum transaminase elevations as indicators of hepatic injury following the administration of drugs Regul. Toxicol. Pharmacol. 27 1998 119-130
7. A. Cheng S.L. Dixon In silico models for the prediction of dose-dependent human hepatotoxicity J. Comput. Aided Mol. Des. 17 2003 811-823
8. R.D. Clark et al. Modelling in vitro hepatotoxicity using molecular interaction fields and SIMCA J. Mol. Graphics Modell. 22 2004 487-497
9. S. Ekins Predicting undesirable drug interactions with promiscuous proteins in silico Drug Discov. Today 9 2004 276-285
10. S. Ekins et al. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors Drug Metab. Dispos. 28 2000 994-1002
11. S. Ekins et al. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors J. Pharmacol. Exp. Ther. 290 1999 429-438
12. S. Wanchana et al. QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method Pharm. Res. 20 2003 1401-1408
13. R.J. Riley et al. Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery Pharm. Res. 18 2001 652-655
14. W.S. Redfern et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32-45
15. S. Ekins et al. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel J. Pharmacol. Exp. Ther. 301 2002 427-434
16. A. Cavalli et al. Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA Study of HERG K+ channel blockers J. Med. Chem. 45 2002 3844-3853
17. R.A. Pearlstein et al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches Bioorg. Med. Chem. Lett. 13 2003 1829-1835
18. A.B. Zolotoy et al. Physicochemical determinants for drug induced blockade of HERG potassium channels: Effect of charge and charge shielding Curr. Med. Chem. Cardiovasc. Hematol. Agents 1 2003 225-241
19. R. Netzer et al. HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery Curr. Opin. Drug Discov. Dev. 6 2003 462-469
20. A.M. Richard DSSTox web site launch: Improving public access to databases for building structure-toxicity prediction models Preclinica 2 2004 103-108
21. J.R. Mitchell et al. Hepatic necrosis caused by furosemide Nature 251 1974 508-511
22. D.K. Dalvie et al. Biotransformation reactions of five-membered aromatic heterocyclic rings Chem. Res. Toxicol. 15 2002 269-299
23. S. Lakhanpal et al. Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma Invest. New Drugs 19 2001 69-76
24. T.M. Alvarez-Diaz J.I. Zheng Mechanism-based inactivation of cytochrome P4503A4 by 4-ipomeanol Chem. Res. Toxicol. 17 2004 150-157
25. E. Kyburz New benzodiazepine receptor ligands: Their pharmacological activities and therapeutic potential Pharmaceutisch Weekblad 121 1986 893-903